Frédérique Menzaghi
2018
In 2018, Frédérique Menzaghi earned a total compensation of $1.2M as Chief Scientific Officer and Senior Vice President, R&D at Cara Therapeutics, a 18% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $212,000 |
|---|---|
| Option Awards | $615,428 |
| Salary | $400,000 |
| Other | $10,799 |
| Total | $1,238,227 |
Menzaghi received $615.4K in option awards, accounting for 50% of the total pay in 2018.
Menzaghi also received $212K in non-equity incentive plan, $400K in salary and $10.8K in other compensation.
Rankings
In 2018, Frédérique Menzaghi's compensation ranked 8,135th out of 14,244 executives tracked by ExecPay. In other words, Menzaghi earned more than 42.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,135 out of 14,244 | 43rd |
Division Manufacturing | 3,213 out of 5,765 | 44th |
Major group Chemicals And Allied Products | 1,205 out of 2,128 | 43rd |
Industry group Drugs | 1,006 out of 1,817 | 45th |
Industry Pharmaceutical Preparations | 784 out of 1,391 | 44th |
Source: SEC filing on April 24, 2019.
Menzaghi's colleagues
We found three more compensation records of executives who worked with Frédérique Menzaghi at Cara Therapeutics in 2018.
News
Cara Therapeutics CEO Derek Chalmers' 2021 pay jumps 250% to $10M
April 22, 2022
Cara Therapeutics CEO Derek Chalmers' 2020 pay slips 15% to $2.9M
April 23, 2021
Cara Therapeutics CEO Derek Chalmers' 2019 pay jumps 23% to $3.4M
April 22, 2020
Cara Therapeutics Chief Medical Officer Joana Goncalves receives $3.7M in 2018
April 24, 2019